NDA 021793 · Meda Pharms
Reglan Odt
Metoclopramide Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 30, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jun 10, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
192
38 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- REGLAN ODT · METOCLOPRAMIDE HYDROCHLORIDE EQ 10MG BASE · TABLET, ORALLY DISINTEGRATING, ORAL · Discontinued
- REGLAN ODT · METOCLOPRAMIDE HYDROCHLORIDE EQ 5MG BASE · TABLET, ORALLY DISINTEGRATING, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Metoclopramide" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Prophylaxis for Aspiration of Gastric Contents.Pivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT02703896 · 1,920 participants · Start Jan 2012 · Primary completion Jan 2012
Drug: Drug either PPIS or H2RA and prokinetics · For: Pulmonary Aspiration of Gastric Contents
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01594749 · 1,015 participants · Start Sep 24, 2012 · Primary completion Nov 3, 2014
Drug: Fosaprepitant dimeglumine; Fosaprepitant Placebo and 5 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.Pivotal-lookingStatus unknown
Instituto Nacional de Cancerologia de MexicoAcademic, hospital or other
NCT03606369 · 560 participants (planned) · Start Nov 5, 2015 · Primary completion Jul 1, 2018
Drug: Palonosetron; Ondansetron · For: Breast Neoplasm; Antineoplastic Agents; Antiemetics and 1 more
Sites: Mexico City, Mexico
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01636947 · 494 participants · Start Dec 12, 2012 · Primary completion Aug 4, 2014
Drug: Aprepitant; Aprepitant Placebo and 4 more · For: Nausea; Vomiting
- Methoclopramide for Gastroesophageal Reflux in Premature InfantsPivotal-lookingCompleted
Nathalie CharpakAcademic, hospital or other
NCT02907632 · 490 participants · Start Apr 26, 2017 · Primary completion Jan 31, 2019
Drug: Metoclopramide; Placebo · For: Gastroesophageal Reflux
Sites: Bogotá, Colombia
- Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second EndoscopyPivotal-lookingStatus unknown
Waihong ChungAcademic, hospital or other
NCT03840057 · 435 participants (planned) · Start Jul 1, 2020 · Primary completion Jun 2021
Drug: Azithromycin Injection; Metoclopramide Injectable Solution and 1 more · For: Gastro Intestinal Bleeding; Upper Gastrointestinal Bleeding
Sites: Providence, Rhode Island
- The Effect of Aprepitant Reducing Postoperative Nausea and VomitingPivotal-lookingStatus unknown
Hospital General TlahuacGovernment (non-federal)
NCT05772676 · 400 participants · Start Dec 1, 2022 · Primary completion Jan 1, 2023
Drug: Aprepitant · For: Obesity; Nausea and Vomiting, Postoperative
Sites: Mexico City, Mexico
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Abdelmonem H, Abdelhay HM, Abdelwadoud GT, et al. · BMC Neurol 2023 · Systematic Review, Network Meta-Analysis
- Efficacy of acupoint injection of metoclopramide for post-chemotherapy vomiting: A systematic review and meta-analysis.
Ai M, Cai Y, Zeng Y, et al. · Medicine (Baltimore) 2024 · Meta-Analysis, Systematic Review
- The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis.
Lau Moon Lin M, Robinson PD, Flank J, et al. · Drug Saf 2016 · Meta-Analysis, Systematic Review
- Aspirin with or without an antiemetic for acute migraine headaches in adults.
Kirthi V, Derry S, Moore RA · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Is metoclopramide beneficial for the postpyloric placement of nasoenteric tubes? A systematic review and meta-analysis of randomized controlled trials.
Ouyang X, Qu R, Hu B, et al. · Nutr Clin Pract 2022 · Meta-Analysis, Systematic Review
- Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis.
Junqueira DR, Bennett D, Huh SY, et al. · Drugs R D 2023 · Meta-Analysis, Systematic Review
Sponsor: Meda Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.